European Journal of Radiology
Volume 62, Issue 2 , Pages 214-219 , May 2007

FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: Correlations and prognostic values

  • Xuan Canh Nguyen

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Present address: Department of Nuclear Medicine, Cho Ray Hospital, 201 B Nguyen Chi Thanh Street, District 5, Ho Chi Minh City, Viet Nam.
    • ,
  • Won Woo Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Nuclear Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Republic of Korea. Tel.: +82 31 787 7672; fax: +82 31 787 4018.
    • ,
  • Jin-Haeng Chung

      Affiliations

    • Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • So Yeon Park

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Sook Whan Sung

      Affiliations

    • Department of Thoracic Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Yu Kyeong Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Young So

      Affiliations

    • Department of Nuclear Medicine, Konkuk University School of Medicine, Chungju, Republic of Korea
    • ,
  • Dong Soo Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • June-Key Chung

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Myung Chul Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Sang Eun Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Received 5 May 2006 ,Revised 15 August 2006 ,Accepted 19 December 2006.

References 

  1. Ramnath N, Hernandez FJ, Tan DF, et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol. 2001;19:4259–4266
  2. AJCC cancer staging manual, 6th ed. NY: Sringer; 2002. p. 167–77.
  3. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39–45
  4. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151–159
  5. Harpole DH, Richards WG, Herndon JE, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg. 1996;61:1470–1476
  6. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–3844
  7. Shankar LK, Sullivan DC. Functional imaging in lung cancer. J Clin Oncol. 2005;23:3203–3211
  8. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology. 1998;207:767–774
  9. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I non-small cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046–1051
  10. Minami K, Saito Y, Imamura H, Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer. 2002;38:51–57
  11. Kawana H, Tamaru J, Tanaka T, et al. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol. 1998;153:505–513
  12. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 2000;6:4073–4081
  13. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348–1352
  14. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–3206
  15. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;23:865–870
  16. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–3260
  17. http://www.intmed.mcw.edu/clincalc/body.html
  18. Chung JH, Cho KJ, Lee SS, et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG-PET results in lung cancer staging. J Nucl Med. 2004;45:999–1003
  19. Higashi K, Ueda Y, Ayabe K, et al. FDG-PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707–714
  20. Patz EF, Connolly J, Herndon J. Prognostic value of thoracic FDG-PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol. 2000;174:769–774
  21. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG-PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–1604
  22. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:13–21
  23. Sasaki R, Komaki R, Macapinlac H, et al. [18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–1143
  24. Wahl RL. Principles of cancer imaging with fluorodexoyglucose. In:  Wahl RL editors. Principles and practice of positron emission tomography. Tokyo: Lippincot Williams and Wilkins; 2002;p. 100–110
  25. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556–565
  26. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med. 2000;27:1778–1785
  27. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99–107
  28. Avril N. Glut1 expression in tissue and (18)F-FDG uptake. J Nucl Med. 2004;45:930–932
  29. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59:4709–4714
  30. Caraco C, Aloj L, Chen LY, Chou JY, Eckelman WC. Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem. 2000;275:18489–18494
  31. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7:369–379
  32. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr. 2002;26:185–190
  33. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414–419
  34. Higashi K, Ueda Y, Yagishita M, et al. FDG-PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85–92
  35. Buck AK, Glatting G, Reske SN. Quantification of 18F-FDG uptake in non-small cell lung cancer: a feasible prognostic marker?. J Nucl Med. 2004;45:1274–1276
  36. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  37. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–1431
  38. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–1721
  39. Eschmann SM, Friedel G, Paulsen F, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?. Eur J Nucl Med Mol Imaging. 2005;

PII: S0720-048X(06)00553-5

doi: 10.1016/j.ejrad.2006.12.008

European Journal of Radiology
Volume 62, Issue 2 , Pages 214-219 , May 2007

Article Tools

* Image Usage & Resolution